← Back to Browse

Guardant Health, Inc.

GH • Healthcare

Compare

About Guardant Health, Inc.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI.

Current Price
$160.05
Market Cap
$13.1B

Quality Assessment

Guardant Health, Inc. is a high-risk healthcare company with a Compass Score of 14. Poor quality metrics and high risk. Not one for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Fair Value

Pro

See whether this stock trades above or below its fair value.

Wall Street View

Consensus
Hold
Analysts
17
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Catalyst Signal

Plus

Recent earnings beats and analyst-upgrade momentum. How it works

Catalyst Score
๐Ÿ”’
EPS Beat Streak
๐Ÿ”’
Net Upgrades (180d)
๐Ÿ”’

See recent earnings beats and analyst-upgrade momentum.

Analyst Track Record

Plus

See each covering analyst's historical hit rate.

Financial Health

Plus

Click any metric for details

See bankruptcy-risk and financial-strength scores for this company.

Growth Projections

Plus
Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

See projected EPS and revenue growth for this company.

Technical Overview

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.